The burgeoning landscape of therapy for excess body fat and type 2 glucose intolerance is currently witnessing considerable attention surrounding both retatrutide and tirzepatide. While both represent novel dual GIP and GLP-1 binding site agonists, significant distinctions in their pharmacological profiles and clinical study results are emerging. R… Read More

Emerging in the arena of obesity therapy, retatrutide is a distinct approach. Unlike many current medications, retatrutide operates as a dual agonist, concurrently targeting both GLP-like peptide-1 (GLP-1) and glucose-responsive insulinotropic hormone (GIP) sensors. This simultaneous engagement encourages several advantageous effects, like enhanced… Read More